{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:31:47Z","timestamp":1791599507499,"version":"4.3.4"},"reference-count":34,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Yunnan Key R & D Program","award":["202403AC100011"],"award-info":[{"award-number":["202403AC100011"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R & D Program of China","doi-asserted-by":"crossref","award":["2025ZD01904400"],"award-info":[{"award-number":["2025ZD01904400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key R & D Program of China","doi-asserted-by":"crossref","award":["2023YFC2306700"],"award-info":[{"award-number":["2023YFC2306700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20473"],"award-info":[{"award-number":["U23A20473"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>HIV-1 integrase strand transfer inhibitors (INSTIs) are pivotal to antiretroviral therapy. However, the emergence of drug-resistant mutations necessitates the development of new agents. Here, we present ACC017 as a novel INSTI candidate. ACC017 demonstrated potent activity against the laboratory-adapted HIV-1IIIB strain (EC50 = 0.59 nM; SI &gt; 34,525) and maintained efficacy against a panel of drug-resistant strains (EC50 range from 0.34 to 9.12 nM) and clinical isolated strains (EC50 range from 0.11 to 1.78 nM). Mechanism of action studies confirmed its ability to inhibit the integrase enzyme (IC50 = 9.19 nM) and effectively block viral genome integration. Notably, in vitro resistance selection primarily yielded D232N and R263K mutations, without the emergence of G140S\/A\/C\/R or Q148H\/R\/K. This promising profile, combined with synergistic interactions with other antiretroviral drugs, positions ACC017 as a potential therapeutic option.<\/jats:p>","DOI":"10.3390\/v18010033","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:22:14Z","timestamp":1766575334000},"page":"33","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-HIV-1 Activity of the Integrase Strand Transfer Inhibitor ACC017"],"prefix":"10.3390","volume":"18","author":[{"given":"Meng-Di","family":"Ma","sequence":"first","affiliation":[{"name":"State Key Laboratory of Genetic Evolution & Animal Models, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China"},{"name":"University of Chinese Academy of Sciences, Beijing 100049, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Hua","family":"Luo","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Genetic Evolution & Animal Models, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yan","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Genetic Evolution & Animal Models, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China"},{"name":"College of Pharmacy, Dali University, Dali 671000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-Cheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Chengdu Aidea Pharma-Tech Co., Ltd., Chengdu 610219, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yan","family":"Long","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Genetic Evolution & Animal Models, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China"},{"name":"University of Chinese Academy of Sciences, Beijing 100049, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Ying","family":"He","sequence":"additional","affiliation":[{"name":"Chengdu Aidea Pharma-Tech Co., Ltd., Chengdu 610219, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu-Meng","family":"Yang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Genetic Evolution & Animal Models, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He-Liang","family":"Fu","sequence":"additional","affiliation":[{"name":"Jiangsu Aidea Pharmaceutical Co., Ltd., Yangzhou 225008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5469-0324","authenticated-orcid":false,"given":"Yong-Tang","family":"Zheng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Genetic Evolution & Animal Models, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"ref_1","unstructured":"(2025, September 14). HIV Data and Statistics. Available online: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/strategic-information\/hiv-data-and-statistics."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Sever, B., Otsuka, M., Fujita, M., and Ciftci, H. (2024). A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202401.1357.v1"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41572-023-00452-3","article-title":"HIV infection","volume":"9","author":"Bekker","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0140-6736(07)60571-6","article-title":"Raltegravir: A new antiretroviral class for salvage therapy","volume":"369","author":"Cahn","year":"2007","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1742-4690-5-114","article-title":"Integrase and integration: Biochemical activities of HIV-1 integrase","volume":"5","author":"Delelis","year":"2008","journal-title":"Retrovirology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41579-021-00586-9","article-title":"Structure and function of retroviral integrase","volume":"20","author":"Maertens","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"116900","DOI":"10.1016\/j.ejmech.2024.116900","article-title":"A mini-review on integrase inhibitors: The cornerstone of next-generation HIV treatment","volume":"279","author":"Shalbi","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.tips.2020.06.003","article-title":"Structural Biology of HIV Integrase Strand Transfer Inhibitors","volume":"41","author":"Passos","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40265-020-01379-9","article-title":"HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety","volume":"80","author":"Scarsi","year":"2020","journal-title":"Drugs"},{"key":"ref_10","first-page":"457","article-title":"2025 update of the drug resistance mutations in HIV-1","volume":"33","author":"Wensing","year":"2025","journal-title":"Top. Antivir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/QCO.0000000000000453","article-title":"Dolutegravir resistance mutations: Lessons from monotherapy studies","volume":"31","author":"Blanco","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1056\/NEJMc1806554","article-title":"Failure of Dolutegravir First-Line ART with Selection of Virus Carrying R263K and G118R","volume":"381","author":"Jensen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1093\/jac\/dkz256","article-title":"A systematic review of the genetic mechanisms of dolutegravir resistance","volume":"74","author":"Rhee","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e00611","DOI":"10.1128\/AAC.00611-20","article-title":"HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants","volume":"64","author":"Smith","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s11904-022-00616-y","article-title":"Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?","volume":"19","author":"Parikh","year":"2022","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/infdis\/jir025","article-title":"HIV-1 integrase inhibitor resistance and its clinical implications","volume":"203","author":"Blanco","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1128\/AAC.01228-07","article-title":"Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro","volume":"52","author":"Malet","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1517\/13543784.17.3.413","article-title":"Raltegravir: An integrase inhibitor for HIV-1","volume":"17","author":"Evering","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/QCO.0b013e32835ba81c","article-title":"Evolution of HIV integrase resistance mutations","volume":"26","author":"Quashie","year":"2013","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40265-014-0206-8","article-title":"Elvitegravir: A review of its use in adults with HIV-1 infection","volume":"74","author":"Deeks","year":"2014","journal-title":"Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/jac\/dkv149","article-title":"Analysis of early resistance development at the first failure timepoint in elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate-treated patients","volume":"70","author":"White","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"106343","DOI":"10.1016\/j.ijantimicag.2021.106343","article-title":"HIV-1 integrase strand transfer inhibitors: A review of current drugs, recent advances and drug resistance","volume":"57","author":"Mbhele","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/bcpt.12828","article-title":"Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance","volume":"121","author":"Llibre","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/cid\/ciz407","article-title":"Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy","volume":"70","author":"Bourgi","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e26371","DOI":"10.1002\/jia2.26371","article-title":"Impact of switching to a dolutegravir-based regimen on body weight changes: Insights from West African adult HIV cohorts","volume":"27","author":"Tiendrebeogo","year":"2024","journal-title":"J. Int. AIDS Soc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","article-title":"Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: Week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ddr.22036","article-title":"Synthesis and anti-HIV activity of non-nucleoside reverse-transcriptase inhibitor DB02 phosphate derivatives based on water-soluble optimization","volume":"84","author":"Wang","year":"2023","journal-title":"Drug Dev. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.apsb.2019.08.009","article-title":"Synthesis and biological evaluation of a series of 2-(((5-akly\/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones as potential HIV-1 inhibitors","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Kang, D.W., Yang, J.X., Kong, L.J., Luo, R.H., Huang, X.S., Zhang, T., Ma, M.D., Feng, D., Wang, Z., and Fang, H. (2022). Structure-Based Discovery and Characterization of a Preclinical Drug Candidate for the Treatment of HIV-1 Infection. Viruses, 14.","DOI":"10.3390\/v14112390"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2174\/1570162X18666200620211922","article-title":"The New NNRTI ACC007 Combined with Lamivudine and Tenofovir Disoproxil Fumarate Show Synergy Anti-HIV Activity In Vitro","volume":"18","author":"Huang","year":"2020","journal-title":"Curr. HIV Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1128\/AAC.40.6.1491","article-title":"Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease","volume":"40","author":"Bilello","year":"1996","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/1\/33\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T05:16:29Z","timestamp":1766726189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/1\/33"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["v18010033"],"URL":"https:\/\/doi.org\/10.3390\/v18010033","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]}}}